THERAPY DOSSIER · th-b69a5e7feccb

AKT1-modified bone marrow-derived mesenchymal stem cells (pMSCV-AKT1-IRES-eGFP retrovirus, MOI 40, 8 microgram/ml polybrene)

Biologic

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Chemical/toxin
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 31889917 ↗2019Reported benefit

Bone Marrow-Derived Mesenchymal Stem Cells Modified with Akt1 Ameliorates Acute Liver GVHD.

MouseChemical/toxinBALB/c (H2d) recipients; bone marrow mesenchymal stem cell donors C57BL/6Femalen = 30 mice in total, 10 per group across three groupsIntravenous, via the tail vein30 minutes after concanavalin A administration

Model: Concanavalin A-induced immune-mediated acute liver injury (20 mg/kg concanavalin A intravenously) used as a model of acute liver graft-versus-host disease

AKT1-modified mesenchymal stem cells outperformed unmodified cells, giving larger reductions in serum ALT and AST, less hepatic necrosis, lower TNF-alpha and IFN-gamma, and better cell homing and survival in the injured liver.

Extraction: extract · Supplied extraction confidence: 0.85. Machine-extracted fields require source verification.

Loading the evidence…